A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-09-23) →
What happened
Aprogen Biologics disclosed convertible bonds to raise US$14.8M, about 78.5% of its market value.
For context, this raise equals about 78.5% of the company's market value, which is the rough scale of potential new-share dilution.
| Instrument | Convertible bonds |
|---|---|
| Raise amount | US$14.8M |
| vs. market value | 78.5% |
| Filed | 2026-09-03, Material event report (rights offering) |
| Source | DART rcept 20260903000316 → open original filing |
Versions of this filing
- 2026-09-03Original (this page)
- 2026-09-11Amendment 1
- 2026-09-23Amendment 2
Source: DART. Information only, not investment advice.